Nu-Med Plus Inc. Com (NUMD) earnings
Quarterly and annual NUMD reports and results, each read against the price at its own news timestamp. Back to the NUMD overview →
14 measured NUMD earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Nu-Med Plus, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | — | |
| Form 10-Q Nu-Med Plus, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Form 10-K Nu-Med Plus, Inc. For: Dec 31 | SEC filing · Form 10-K | — | — | |
| Form NT 10-K Nu-Med Plus, Inc. For: Dec 31 | SEC filing · Form NT | — | — | |
| Form 10-Q Nu-Med Plus, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | — | |
| Form 10-Q Nu-Med Plus, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | +0.00% | |
| Form 10-Q Nu-Med Plus, Inc. For: Mar 31 | SEC filing · Form 10-Q | — | — | |
| Form 10-K Nu-Med Plus, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -2.37% | |
| Form 10-Q Nu-Med Plus, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | -8.86% | |
| Form 10-Q Nu-Med Plus, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.64% | +2.64% | |
| Form NT 10-Q Nu-Med Plus, Inc. For: Jun 30 | SEC filing · Form NT | — | +0.00% | |
| Form 10-Q Nu-Med Plus, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Form 10-K Nu-Med Plus, Inc. For: Dec 31 | SEC filing · Form 10-K | — | +0.00% | |
| Form 10-Q Nu-Med Plus, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | — |
Keep exploring
More NUMD: analyst actions → · SEC filings → · NUMD overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Aridis Pharmaceuticals Inc. (ARDS) | 28 | 0.00% | 48% |
| Evelo Biosciences, Inc. (EVLO) | 28 | -3.02% | 36% |
| RESPIRERX PHARMA INC (RSPI) | 28 | 0.00% | 37% |
| Axim Biotechnologies, Inc (AXIM) | 27 | 0.00% | 16% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.